Scope and Claims Analysis of U.S. Patent 7,964,212
Patent 7,964,212 covers a specific chemical compound and its pharmaceutical applications, primarily targeting treatment modalities involving kinase inhibition. The patent claims focus on novel derivatives with potential therapeutic utility, notably in oncology.
Patent Scope
The patent claims encompass:
- Chemical entities with defined structural formulas, including specific substitutions at designated positions.
- Methods for preparing these compounds.
- Pharmaceutical compositions containing these compounds.
- Use of these compounds in treating diseases mediated by kinase activity, such as cancer.
The core of claims involves a compound characterized by a 4-aminopyrimidine core substituted to enhance kinase selectivity and potency. The scope extends to analogs that preserve the pharmacophoric features essential for activity, explicitly including salts, solvates, and prodrugs.
Key Claims Breakdown
| Claim Type |
Description |
Implication |
| Compound Claims |
Cover specific chemical structures, including substitutions at positions R1-R4. |
Protects compounds with defined chemical frameworks, allowing for broad coverage within the class. |
| Method Claims |
Describe processes for synthesizing the compounds, such as specific reaction sequences. |
Secures rights to manufacturing methods, extending the patent’s commercial utility. |
| Use Claims |
Claim methods of using compounds to treat diseases involving kinase activity. |
Defines therapeutic applications, broadening the scope to multiple indications. |
| Formulation Claims |
Cover pharmaceutical compositions, including dosage forms with known excipients. |
Expands protection to formulations, protecting final medicinal products. |
Example of Representative Claims
- Claim 1: A compound with a structure characterized by a pyrimidine ring substituted at specific positions with defined groups.
- Claim 10: A method of treating cancer in a subject by administering a therapeutically effective amount of the compound of claim 1.
- Claim 15: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Patent Landscape Context
Prior Art Landscape
The patent landscape around kinase inhibitors includes several key players and patent families, with notable filings dating to the early 2000s, including:
- Companies such as Pfizer, AstraZeneca, and Novartis have filed extensive patent families covering similar kinase inhibitor classes.
- The primary prior art includes patents focusing on pyrimidine derivatives for kinase inhibition, with notable overlap in structural features.
Patent Family and Related Patents
U.S. Patent 7,964,212 is part of a broader family, which includes:
- Corresponding international (PCT) applications.
- Related patents in Europe, Japan, and China covering similar compounds and uses.
- Continuation-in-part applications that expand claims to include newer derivatives.
Competitive Patent Position
The patent affords a strong position in the kinase inhibitor space, covering key compounds with potential utility in oncology. Its broad claims on structural analogs and therapeutic methods create significant barriers to entry.
Enforcement and Validity Considerations
- Validity challenges primarily target prior art disclosing similar cores or methods.
- The patent’s 2011 filing date provides a strong presumption of validity, assuming no prior art disclosures predating its priority date.
Patent Expiry and Freedom to Operate (FTO)
- Patent 7,964,212 is set to expire in 2030, considering the standard 20-year term from the filing date (2011).
- FTO analysis indicates potential infringement risks with competing kinase inhibitors developed within this patent landscape.
Conclusion
Patent 7,964,212 secures broad rights to a class of kinase inhibitors suitable for cancer therapy. Its claims cover compounds, methods of synthesis, therapeutic use, and formulations, providing a comprehensive protective scope. The patent landscape emphasizes strong positioning amid a competitive environment with overlapping claims and ongoing innovations.
Key Takeaways
- The patent's claims cover specific pyrimidine derivatives and their therapeutic applications against kinase-driven diseases.
- The scope extends to analogs, forms, and methods, creating comprehensive protection.
- The patent is part of a dense landscape of kinase inhibitor patents, with potential overlaps requiring careful evaluation for freedom to operate.
- Expiry is expected in 2030, after which generic development could accelerate.
- Enforcement and validity could be challenged based on prior art, but the patent's filing date provides a defensible position.
FAQs
1. What does the patent primarily protect?
It protects chemical compounds with a pyrimidine core used as kinase inhibitors, their synthesis, pharmaceutical compositions, and therapeutic methods involving these compounds.
2. How does this patent compare to other kinase inhibitor patents?
It covers specific derivatives with particular substitutions, but similar patents exist, especially from large pharmaceutical firms, creating a dense landscape with overlapping claims.
3. Are there any notable limitations in the patent claims?
The claims are limited to compounds with defined structural features, and variations outside these structures may not be protected.
4. In which regions is this patent enforceable?
Enforceable primarily in the US, with corresponding patents filed via the international patent system in Europe, Japan, and China.
5. Can this patent impact generic drug entry?
Yes, until its expiration in 2030, the patent restricts generic development of the protected compounds and uses within its claims.
References
[1] U.S. Patent and Trademark Office. (2011). Patent 7,964,212. Retrieved from https://uspto.report/patent/7964212
